Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries.
Hrnciarova T, Drahota J, Spelman T, Hillert J, Lycke J, Kubala Havrdova E, Recmanova E, Adamkova J, Mares J, Libertinova J, Pavelek Z, Hradilek P, Ampapa R, Stetkarova I, Peterka M, Martinkova A, Stourac P, Grunermelova M, Vachova M, Dufek M, Horakova D. Hrnciarova T, et al. Among authors: dufek m. Mult Scler Relat Disord. 2023 Aug;76:104803. doi: 10.1016/j.msard.2023.104803. Epub 2023 Jun 12. Mult Scler Relat Disord. 2023. PMID: 37329786
[Diabetes insipidus followed, after 4 years, with dysarthria and mild right-sided hemiparesis--the first clinical signs of Erdheim-Chester disease. Description and depiction of a case with a review of information on the disease].
Adam Z, Balsíková K, Pour L, Krejcí M, Svacina P, Dufek M, Kren L, Hermanová M, Moulis M, Vanícek J, Neubauer J, Mechl M, Prásek J, Stanícek J, Koukalová R, Hájek R, Mayer J. Adam Z, et al. Among authors: dufek m. Vnitr Lek. 2009 Dec;55(12):1173-88. Vnitr Lek. 2009. PMID: 20070034 Review. Czech.
Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS.
Horakova D, Rockova P, Jircikova J, Dolezal T, Vachova M, Hradilek P, Valis M, Sucha J, Martinkova A, Ampapa R, Grunermelova M, Stetkarova I, Stourac P, Mares J, Dufek M, Kmetova E, Adamkova J, Hrnciarova T. Horakova D, et al. Among authors: dufek m. Mult Scler Relat Disord. 2019 Oct;35:196-202. doi: 10.1016/j.msard.2019.08.003. Epub 2019 Aug 3. Mult Scler Relat Disord. 2019. PMID: 31400559
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
The Czech National MS Registry (ReMuS): Data trends in multiple sclerosis patients whose first disease-modifying therapies were initiated from 2013 to 2021.
Stastna D, Drahota J, Lauer M, Mazouchova A, Menkyova I, Adamkova J, Ampapa R, Dufek M, Grunermelova M, Hradilek P, Kubala Havrdova E, Mares J, Martinkova A, Pavelek Z, Peterka M, Recmanova E, Rockova P, Stetkarova I, Stourac P, Vachova M, Horakova D. Stastna D, et al. Among authors: dufek m. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2024 Sep;168(3):262-270. doi: 10.5507/bp.2023.015. Epub 2023 Apr 28. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2024. PMID: 37114703 Free article.
Is breastfeeding in MS harmful or not? An answer from real-world Czech data.
Hradilek P, Zapletalova O, Hanulikova P, Havrdova EK, Woznicova I, Mazouchova A, Drahota J, Lauer M, Stetkarova I, Valis M, Libertinova J, Stourac P, Adamkova J, Ampapa R, Vachova M, Dufek M, Martinková A, Peterka M, Recmanova E, Mares J, Horakova D. Hradilek P, et al. Among authors: dufek m. Mult Scler Relat Disord. 2023 Aug;76:104790. doi: 10.1016/j.msard.2023.104790. Epub 2023 Jun 16. Mult Scler Relat Disord. 2023. PMID: 37348317
Inhibition of CD40L with Frexalimab in Multiple Sclerosis.
Vermersch P, Granziera C, Mao-Draayer Y, Cutter G, Kalbus O, Staikov I, Dufek M, Saubadu S, Bejuit R, Truffinet P, Djukic B, Wallstroem E, Giovannoni G; Frexalimab Phase 2 Trial Group. Vermersch P, et al. Among authors: dufek m. N Engl J Med. 2024 Feb 15;390(7):589-600. doi: 10.1056/NEJMoa2309439. N Engl J Med. 2024. PMID: 38354138 Clinical Trial.
Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study.
Kappos L, Gold R, Miller DH, MacManus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Eraksoy M, Meluzinova E, Dufek M, Yang M, Dawson K, O'Neill GN. Kappos L, et al. Among authors: dufek m. Mult Scler. 2012 Mar;18(3):314-21. doi: 10.1177/1352458511421054. Epub 2011 Aug 30. Mult Scler. 2012. PMID: 21878455 Clinical Trial.
104 results